Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense [Yahoo! Finance]
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: Yahoo! Finance
The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer. "This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities," said Marc Hedrick, President & CEO of Plus Therapeutics. "In 2023, the company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024," Hedrick added. The DoD Peer Reviewed Cancer Research Program (PRCRP) Advancing Cancer Care through Clinical Trials Award will be utilized to fund a Phase 1 dose escalation trial to address the FY23 PRCRP Topic Area of Pediatric Brain Tumors. This study will investigate a novel therapeutic, Rhenium (186Re) Obisbemeda (186RNL), delivered by Convection Enhanced Delivery, for supratentorial recurrent, refractory, or progressive pediatric high-grade glioma and ependymoma. Patient
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseGlobeNewswire
- Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamGlobeNewswire
- Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceGlobeNewswire
- Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic [Yahoo! Finance]Yahoo! Finance
PSTV
Earnings
- 10/31/23 - Miss
PSTV
Sec Filings
- 3/14/24 - Form 8-K
- 3/13/24 - Form 8-K
- 3/8/24 - Form S-1/A
- PSTV's page on the SEC website